Salem Investment Counselors Inc. bought a new stake in Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 45,402 shares of the company's stock, valued at approximately $230,000. Salem Investment Counselors Inc. owned 0.28% of Alpha Cognition as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently bought and sold shares of ACOG. Rosalind Advisors Inc. bought a new position in shares of Alpha Cognition during the 4th quarter worth approximately $1,489,000. National Bank of Canada FI acquired a new stake in Alpha Cognition during the 4th quarter valued at $69,000. Aristides Capital LLC bought a new position in Alpha Cognition during the fourth quarter worth $1,178,000. ADAR1 Capital Management LLC acquired a new position in shares of Alpha Cognition in the fourth quarter valued at $1,204,000. Finally, Altium Capital Management LLC bought a new position in shares of Alpha Cognition in the fourth quarter valued at about $1,620,000.
Alpha Cognition Trading Down 1.6%
ACOG traded down $0.15 during trading on Wednesday, hitting $8.95. The stock had a trading volume of 41,260 shares, compared to its average volume of 99,888. The stock has a 50 day simple moving average of $7.33. Alpha Cognition Inc. has a one year low of $3.75 and a one year high of $11.40. The company has a market capitalization of $143.38 million, a price-to-earnings ratio of -7.46 and a beta of 2.79.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.38. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.50 million.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Raymond James Financial upgraded shares of Alpha Cognition to a "moderate buy" rating in a research note on Tuesday, March 25th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alpha Cognition in a research report on Friday, May 16th.
Read Our Latest Stock Report on Alpha Cognition
About Alpha Cognition
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
See Also
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
